AI-Powered histopathology slide image interpretation in oncology: A comprehensive knowledge mapping and bibliometric analysis

人工智能在肿瘤组织病理切片图像判读中的应用:一项综合知识图谱构建和文献计量分析

阅读:1

Abstract

OBJECTIVES: To map global research on AI-driven histopathological image interpretation in oncology (2000-2024). METHODOLOGY: Scopus-based bibliometrics using Boolean queries; data exported, cleaned, and analyzed in VOSviewer. RESULTS: The dataset included 1874 publications, surging after 2015. China (n = 561) and the United States (n = 467) led output; leading institutions included Harvard Medical School and the Chinese Academy of Sciences. Top journals were Scientific Reports, Cancers, and IEEE Access; the corpus H-index was 112. Collaboration networks intensified, especially U.S.-Asia. Keyword mapping showed four clusters: (1) deep learning for breast cancer/CNN diagnostics; (2) transfer learning/feature extraction; (3) prognostic modeling/tumor microenvironment; and (4) digital infrastructure/explainable AI. Overlay analyses traced a shift from classical machine learning to transformers and multimodal models integrating molecular and clinical data; emerging themes include semantic segmentation, self-supervised learning, and therapy-response prediction. Applications spanned breast, prostate, colorectal, head-neck, gynecologic, and gastrointestinal/liver cancers. Models primarily used whole-slide images (e.g., TCGA) and multi-omics; algorithms included CNNs, deep learning, classical machine learning, and weakly supervised approaches. Evidence ranged from proof-of-concept to multicenter validation and workflow integration; adoption remains constrained by data standardization, interpretability, and regulation. Clinically, AI improved diagnostic accuracy/efficiency and supported personalization via multi-omics. Bibliographic coupling revealed three clusters: clinical/translational journals; engineering/computational outlets; and interdisciplinary venues linking algorithmic innovation with digital pathology. CONCLUSIONS: AI histopathology is advancing toward clinical-grade deployment, propelled by collaboration and methodological innovation, yet limited by data standards, explainability, and regulatory requirements.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。